Advanced search
Publication Cover
Expert Review of Anti-infective Therapy Volume 10, 2012 - Issue 11
Submit an article Journal homepage
875
Views
11
CrossRef citations to date
0
Altmetric
Editorial

Influenza antivirals and resistance: the next 10 years?

Aeron C Hurt WHO Collaborating Centre for Reference and Research on Influenza, North Melbourne, Victoria 3051, Australia and Monash University, School of Applied Sciences, Churchill, Victoria 3842, Australia. [email protected]
,
Jeff Butler WHO Collaborating Centre for Reference and Research on Influenza, North Melbourne, Victoria 3051, Australia
,
Anne Kelso WHO Collaborating Centre for Reference and Research on Influenza, North Melbourne, Victoria 3051, Australia
&
Ian G Barr WHO Collaborating Centre for Reference and Research on Influenza, North Melbourne, Victoria 3051, Australia and Monash University, School of Applied Sciences, Churchill, Victoria 3842, Australia
Pages 1221-1223 | Published online: 10 Jan 2014

References

  • Fry AM, Pérez A, Finelli L. Use of intravenous neuraminidase inhibitors during the 2009 pandemic: results from population-based surveillance. JAMA 306(2), 160–162 (2011).
  • Furuta Y, Takahashi K, Kuno-Maekawa M et al. Mechanism of action of T-705 against influenza virus. Antimicrob. Agents Chemother. 49(3), 981–986 (2005).
  • Kiso M, Takahashi K, Sakai-Tagawa Y et al. T-705 (favipiravir) activity against lethal H5N1 influenza A viruses. Proc. Natl Acad. Sci. USA 107(2), 882–887 (2010).
  • Smee DF, Hurst BL, Wong MH et al. Effects of the combination of favipiravir (T-705) and oseltamivir on influenza A virus infections in mice. Antimicrob. Agents Chemother. 54(1), 126–133 (2010).
  • Wright SG. Protozoan infections of the gastrointestinal tract. Infect. Dis. Clin. North Am. 26(2), 323–339 (2012).
  • Rossignol JF, La Frazia S, Chiappa L, Ciucci A, Santoro MG. Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at the post-translational level. J. Biol. Chem. 284(43), 29798–29808 (2009).
  • Ashton LV, Callan RL, Rao S, Landolt GA. In vitro susceptibility of canine influenza A (H3N8) virus to nitazoxanide and tizoxanide. Vet. Med. Int. 2010, pii: 891010 (2010).
  • Bright RA, Medina MJ, Xu X et al. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 366(9492), 1175–1181 (2005).
  • Meijer A, Lackenby A, Hungnes O et al.; European Influenza Surveillance Scheme. Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007–08 season. Emerging Infect. Dis. 15(4), 552–560 (2009).
  • Hurt AC, Ernest J, Deng YM et al. Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa. Antiviral Res. 83(1), 90–93 (2009).
  • Itoh Y, Shinya K, Kiso M et al. In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 460(7258), 1021–1025 (2009).
  • Lackenby A, Moran Gilad J, Pebody R et al. Continued emergence and changing epidemiology of oseltamivir-resistant influenza A(H1N1)2009 virus, United Kingdom, winter 2010/11. Euro Surveill. 16(5), pii: 19784 (2011).
  • Storms AD, Gubareva LV, Su S et al.; US Antiviral Resistance Surveillance Working Group. Oseltamivir-resistant pandemic (H1N1) 2009 virus infections, United States, 2010–11. Emerging Infect. Dis. 18(2), 308–311 (2012).
  • Hurt AC, Hardie K, Wilson NJ et al. Community transmission of oseltamivir-resistant A(H1N1)pdm09 influenza. N. Engl. J. Med. 365(26), 2541–2542 (2011).
  • Sleeman K, Sheu TG, Moore Z et al. Influenza B viruses with mutation in the neuraminidase active site, North Carolina, USA, 2010–11. Emerging Infect. Dis. 17(11), 2043–2046 (2011).
  • Yen HL, Herlocher LM, Hoffmann E et al. Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility. Antimicrob. Agents Chemother. 49(10), 4075–4084 (2005).
  • Pfeiffer JK, Kirkegaard K. A single mutation in poliovirus RNA-dependent RNA polymerase confers resistance to mutagenic nucleotide analogs via increased fidelity. Proc. Natl Acad. Sci. USA 100(12), 7289–7294 (2003).
  • Feigelstock DA, Mihalik KB, Feinstone SM. Selection of hepatitis C virus resistant to ribavirin. Virol. J. 8, 402 (2011).
  • Korba BE, Elazar M, Lui P, Rossignol JF, Glenn JS. Potential for hepatitis C virus resistance to nitazoxanide or tizoxanide. Antimicrob. Agents Chemother. 52(11), 4069–4071 (2008).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.